Literature DB >> 33364732

Adiponectin resistance parameter as a marker for high normal blood pres-sure and hypertension in patients with metabolic syndrome.

S Stojanovic1, M Deljanin-Ilic1, S Ilic1, M Stefanovic2, D Petrovic3, V Petrovic2, M Stojanovic1.   

Abstract

INTRODUCTION: The different degrees of adiponectin/insulin sensitivity and dysfunctional adipose tissue lead to the development of hypertension (HT). This study aimed to determine adiponectin (AD) concentration in patients with metabolic syndrome (MetS) and high-normal blood pressure or hypertension and to investigate the importance of Homeostatic Model Assessment-AD (HOMA-AD) index in assessing adiponectin/insulin resistance in hypertension.
METHODS: This cross-sectional study involved 150 subjects divided into two groups: with MetS (and high-normal blood pressure, n =50; and HT, n =50), and controls without MetS (n =50). In all subjects, serum adiponectin concentration was measured by enzyme-linked immunosorbent assay method. Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) and HOMA-AD index were calculated.
RESULTS: The results showed that, compared to the control group, serum AD concentrations were significantly lower in patients with MetS and high-normal blood pressure (p =0.008), and the lowest in group MetS and HT (p =0.001). High AD levels and low HOMA-AD were significantly associated with decreased blood pressure values. In patients with MetS, the value of HOMA-AD≥1.13 was associated with a higher risk of developing high-normal blood pressure. Furthermore, the value of HOMA-AD≥2.63 was associated with a higher risk of developing hypertension.
CONCLUSIONS: Hypoadiponectinemia is associated with hypertension, especially in the early stages of the disease. The serum AD levels and HOMA-AD index may be useful markers for identifying patients at risk for high-normal blood pressure and hypertension. HIPPOKRATIA 2020, 24(1): 3-7. Copyright 2020, Hippokratio General Hospital of Thessaloniki.

Entities:  

Keywords:  HOMA-AD index; Homeostatic Model Assessment-adiponectin; adiponectin resistance; biochemical marker; blood pressure

Year:  2020        PMID: 33364732      PMCID: PMC7733364     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  25 in total

1.  2018 ESC/ESH Guidelines for the management of arterial hypertension.

Authors:  Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis L Clement; Antonio Coca; Giovanni de Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre E Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland E Schmieder; Evgeny Shlyakhto; Costas Tsioufis; Victor Aboyans; Ileana Desormais
Journal:  Eur Heart J       Date:  2018-09-01       Impact factor: 29.983

2.  Tumor necrosis factor-α impairs adiponectin signalling, mitochondrial biogenesis, and myogenesis in primary human myotubes cultures.

Authors:  Tahnee Sente; An M Van Berendoncks; Erik Fransen; Christiaan J Vrints; Vicky Y Hoymans
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-02-26       Impact factor: 4.733

Review 3.  Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk.

Authors:  Gema Frühbeck; Victoria Catalán; Amaia Rodríguez; Javier Gómez-Ambrosi
Journal:  Adipocyte       Date:  2017-12-05       Impact factor: 4.534

Review 4.  Adiponectin, a unique adipocyte-derived factor beyond hormones.

Authors:  Norikazu Maeda; Tohru Funahashi; Yuji Matsuzawa; Iichiro Shimomura
Journal:  Atherosclerosis       Date:  2019-11-02       Impact factor: 5.162

5.  HOMA-Adiponectin Closely Associates with Cardiometabolic Risk Markers in Middle-Aged Indians with Metabolic Syndrome.

Authors:  Joyita Banerjee; Yogita Dhas; Neetu Mishra
Journal:  Exp Clin Endocrinol Diabetes       Date:  2020-03-18       Impact factor: 2.949

6.  The HOMA-Adiponectin (HOMA-AD) Closely Mirrors the HOMA-IR Index in the Screening of Insulin Resistance in the Brazilian Metabolic Syndrome Study (BRAMS).

Authors:  Brunna Sullara Vilela; Ana Carolina Junqueira Vasques; Roberta Soares Lara Cassani; Adriana Costa E Forti; José Carlos Pareja; Marcos Antonio Tambascia; Bruno Geloneze
Journal:  PLoS One       Date:  2016-08-04       Impact factor: 3.240

7.  Association of Metabolic Syndrome with the Adiponectin to Homeostasis Model Assessment of Insulin Resistance Ratio.

Authors:  Yu-Song Ding; Shu-Xia Guo; Ru-Lin Ma; Shu-Gang Li; Heng Guo; Jing-Yu Zhang; Mei Zhang; Jia-Ming Liu; Jia He; Yi-Zhong Yan; Wen-Jie Zhang; Lie-Gang Liu
Journal:  Mediators Inflamm       Date:  2015-10-18       Impact factor: 4.711

8.  Adiponectin and its receptors are involved in hypertensive vascular injury.

Authors:  Ruimin Guo; Min Han; Juan Song; Jun Liu; Yanni Sun
Journal:  Mol Med Rep       Date:  2017-10-25       Impact factor: 2.952

Review 9.  The Global Epidemic of the Metabolic Syndrome.

Authors:  Mohammad G Saklayen
Journal:  Curr Hypertens Rep       Date:  2018-02-26       Impact factor: 5.369

10.  Impressic Acid, a Lupane-Type Triterpenoid from Acanthopanax koreanum, Attenuates TNF-α-Induced Endothelial Dysfunction via Activation of eNOS/NO Pathway.

Authors:  Sun Woo Jin; Hoa Thi Pham; Jae Ho Choi; Gi Ho Lee; Eun Hee Han; Young Ho Cho; Young Chul Chung; Young Ho Kim; Hye Gwang Jeong
Journal:  Int J Mol Sci       Date:  2019-11-16       Impact factor: 5.923

View more
  1 in total

Review 1.  Adiponectin System (Rescue Hormone): The Missing Link between Metabolic and Cardiovascular Diseases.

Authors:  Meneerah Abdulrahman Aljafary; Ebtesam Abdullah Al-Suhaimi
Journal:  Pharmaceutics       Date:  2022-07-07       Impact factor: 6.525

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.